Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic Cancer

July 19th 2021

Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.

CHECKMATE649: Safety Profile and Toxicity Management

July 19th 2021

Thought leaders in gastric and GEJ cancers review safety outcomes from the CHECKMATE649 trial presented at the 2021 ASCO annual meeting.

CHECKMATE649: Trial Design and Efficacy Data

July 19th 2021

Key opinion leader in gastric cancer, Daniel Catenacci, MD, leads a discussion on the study design, patient population, and results from the CHECKMATE649 trial of nivolumab and chemotherapy in patients with gastric or GEJ cancers.

Wainberg Weighs In on Advances in HER2+ GI Cancers

July 12th 2021

Dr. Wainberg discusses factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more.

Recent FDA Approvals in Gastric and GEJ Cancers

July 12th 2021

Daniel Catenacci, MD, and Sam Klempner, MD, consider the overall impact of recently approved immunotherapy-based regimens for gastric and gastroesophageal junction cancers.

Historical Perspective on Treatment of Gastric and GEJ Cancers

July 12th 2021

Experts in the management of gastric cancer provide a historical perspective on available treatment options.

Bekaii-Saab Breaks Down Significant Developments in the Realm of Gastrointestinal Cancers

July 8th 2021

Tanios Bekaii-Saab, MD, spotlights the recent developments made in gastrointestinal cancers.

GI Cancer Armamentarium Gains Traction With Immunotherapy, Targeted Agents

July 7th 2021

Jimmy Hwang, MD, discusses the frontline indications for checkpoint inhibitors in gastric cancer and their effect on subsequent treatment decisions, the growth of targeted therapy across gastrointestinal cancers, and expectations for future research and development.

Novel Combination May Break Outcomes Stalemate in Pancreatic Cancer

July 7th 2021

Therapeutic breakthroughs for patients with metastatic pancreatic cancer have eluded investigators for decades, with chemotherapeutic combination strategies serving as the insurmountable standard of care.

Merck Withdraws Pembrolizumab Third-Line Gastric Indication in the United States

July 6th 2021

Merck has announced plans to withdraw the accelerated approval indication for pembrolizumab in the treatment of select patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express a PD-L1 combined positive score of 1 or more, and who have progressed on or after 2 or more previous lines of therapy, including fluoropyrimidine- and platinum-containing chemotherapy, and HER2-/neu-targeted therapy, if appropriate.

RWJBarnabas Health Pioneers Innovative Pancreatic Cyst Surveillance Program

July 5th 2021

The incidental identification of pancreatic cysts has become more common with the increasing use of imaging modalities in clinical practice.

GSK2636771/Paclitaxel Combo Demonstrates Early Promise in Advanced PTEN-Deficient Gastric Cancer

July 3rd 2021

The novel PI3Kß inhibitor GSK2636771 plus paclitaxel led to encouraging clinical activity as well as a tolerable safety profile in patients with PTEN-deficient advanced gastric cancer who progressed following frontline chemotherapy.

Tislelizumab, TTF Studies Poised to Address HCC Questions

July 2nd 2021

The optimal sequence of therapies in the second- or later-line settings for patients with hepatocellular carcinoma remains unclear.

Frontline Pemigatinib Under Investigation in Advanced FGFR2+ Cholangiocarcinoma

July 2nd 2021

Single-agent pemigatinib is being compared with gemcitabine plus cisplatin in patients with unresectable and/or metastatic cholangiocarcinoma whose tumor harbor FGFR2 fusions or rearrangements in the ongoing, phase 3 FIGHT-302 trial.

Dr. Hwang on Considerations for Second-Line Treatment in Gastric/GEJ Cancer

July 1st 2021

Jimmy Hwang, MD, discusses considerations for second-line treatment in gastric/gastroesophageal junction cancer.

Lenvatinib Treatment Can Continue in Unresectable HCC With Child–Pugh Class-B Liver Function

July 1st 2021

Lenvatinib can continue to be administered in patients with unresectable hepatocellular carcinoma that has Child-Pugh class B liver function, as they experienced a similar tumor size reduction as their Child-Pugh class A counterparts in a post-hoc analysis of the phase 3 REFLECT trial.

Pembrolizumab/Lenvatinib Regimen Being Tested in Advanced Gastroesophageal Adenocarcinoma

July 1st 2021

Frontline pembrolizumab plus lenvatinib, and chemotherapy is being tested against chemotherapy alone in patients with advanced gastroesophageal adenocarcinoma, as part of the international, 2-part, phase 3 LEAP-015 trial.

FDA Accepts NDA for Surufatinib for Advanced Neuroendocrine Tumors

July 1st 2021

The FDA has accepted the filing of the new drug application for surufatinib as a potential therapeutic option for patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Frontline Lenvatinib Shows Superiority to Sorafenib in HCC in Real-World Setting

June 30th 2021

Lenvatinib demonstrated superiority to sorafenib in the first-line setting for patients with unresectable hepatocellular carcinoma, according to results of a propensity score matching analysis.

Defining Oligometastatic Gastroesophageal Cancer May Provide Clarity for Treatment Advances

June 30th 2021

The debate continues as to how to define oligometastatic disease and whether it represents a unique stage between limited-stage and widely metastatic disease.